Pipeline

Biocytogen is committed to developing innovative antibody drugs that meet the needs of patients, focusing on oncology, autoimmune, inflammatory, metabolic and and other diseases. Taking full advantage of its unique advantage in innovative drug development, the company now has more than 10 R & D pipelines including monoclonal antibodies, bispecific antibodies, ADC drugs and so on. Our pipeline is supported by a strong clinical development team and abundant clinical resources.

Candidate

Target

Combination

Indication

Pre-clinical

Upcoming Milestone

Rights

News/Press Release



Clinical-stage drug Candidates
 


YH003



CD40



PD-1 Melanoma Global MRCT

Phase II

2021 Q4 Patient
Recruitment
Global Findings From Anti-CD40 Clinical Trials



PD-1 Pancreatic
cancer
Global MRCT

Phase II

2021 Q4 Patient
Recruitment
Monotherapy
Solid tumors China  Phase I 2021 Q3 Patient
Recruitment
PD-1+
YH001
Solid tumors Australia

IND

2021 Q4 Patient Recruitment
YH001


CTLA-4


PD-1 Non-small-cell
lung cancer
(NSCLC)
Global MRCT

Phase II

2021 Q4 Patient
Recruitment
Global


Findings From Anti-CTLA-4 mAb Clinical Trials


PD-1 Hepatocellular
carcinoma
(HCC)
Global MRCT

Phase II

 

2021 Q4 Patient
Recruitment
Monotherapy Solid tumors China 

Phase I

2022 Q1
Complete Phase I
trial
YH002


OX40


Monotherapy  Solid Tumors Australia

Phase 1

2021 Q4
Complete Phase I
trial
Global
Monotherapy Solid Tumors China/USA

Phase 1

Launch based on
clinical results in
Australia
YH001 Solid Tumors China/Australia

IND

2021 Q4 Patient
Recruitment
YH004

4-1BB

PD-1 Hematological
malignancies
Australia

Phase 1

2021 Q4 Patient
Recruitment
Global
PD-1 Solid tumors Australia/China

Phase 1

 

2021 Q4 Patient
Recruitment
YH005-ADC Claudin18.2-
ADC
Solid tumors Australia

IND -> Phase 1

2021 Q3
Receive IND
approval
Remegen
Preclinical drug candidates
 
 
 
YH008 PD-1/CD40
(bispecific
antibody)
  Solid tumors CMC Global 
YH006 CTLA-4/
OX40
(bispecific
antibody)
  Solid Tumors CMC   Global    
YH009 RSV   Prevention/
Treatment for
RSV infection 
CMC Global 
YH010 PD-L1/IL-12   Solid Tumors Discovery   Global    
YH011 PD-L1/
cytokine
  Solid Tumors Discovery   GeneQuantum Healthcare  
YH012 Bispecific
antibody
ADC
  Solid tumors Discovery   Global   
YH013 Bispecific
antibody
ADC
Solid tumors Discovery Global 

 

Back to top